conservative care, but she developed worsening respiratory symptoms, and subsequently died cancer-free from end-stage lung disease.
In order to test whether short telomeres may predispose to radiation sensitivity, we used a modified cell survival assay that is used in the diagnosis of double-strand break syndromes such as ataxia-telangiectasia (A-T) (1, 4) . We examined lymphoblastoid cells derived from 7 other telomerase and telomere gene mutation carriers (Fig. 1C) . Four of the carriers were asymptomatic, 2 had IPF, and 1 had bone marrow failure. Cells from these subjects showed significantly compromised survival compared to controls and were similarly sensitive to A-T on average ( Fig. 1D and E) . In 3 of 7 cases (43%), the surviving fraction at 1 Gy fell at or below 21%, a threshold considered to be diagnostic of A-T in some settings (1) . Neither the age nor the extent of the telomere defect predicted the 1-Gy surviving fraction.
Radiation sensitivity and radiation necrosis are rare complications of radiation therapy, but they are well documented in patients with defective DNA doublestrand break repair such as A-T (5). The data we show here indicate that patients with short telomere syndromes are similarly sensitive to radiation. To our knowledge, this is the first report of radiation necrosis in a telomerase mutation carrier. Sensitivity to radiation in the setting of telomere length abnormalities was first documented in telomerase null mice with short telomeres (6), and our data highlight the relevance of these observations in clinical settings.
Syndromes marked by short telomeres manifest as IPF, emphysema, and aplastic anemia (7) . Mutations in telomere and telomerase genes are the most common cause of familial pulmonary fibrosis cases, accounting for one-third of cases (7); they also rival alpha-1 antitrypsin deficiency as a risk factor for emphysema (8) . Short telomere syndrome patients most often present in mid-to-late adulthood and have no associated dysmorphic features. A cancer diagnosis is estimated to affect up to 10% of severe cases, such as in dyskeratosis congenita, and predominantly manifests as myelodysplasia-acute myeloid leukemia and, more rarely, squamous cell head and neck carcinomas (9) . There are sparse data regarding cancer treatment outcomes in this population. After bone marrow transplantation, pulmonary fibrosis is a nearly uniform complication, and lung shielding has evolved as a standard to minimize this risk (10) . Awareness of this genetic diagnosis is important in clinical settings, where ionizing radiation is used such as in assessing the risk of X ray-based imaging as a screening tool in pulmonary fibrosis, as well as in a preference for radiation-sparing regimens in hematopoietic stem cell transplantation. Patients suspected of having telomere syndromes and who have a personal or family history of IPF-emphysema, especially, or myelodysplastic syndrome, should be identifiable by telomere length measurement combined with genetic testing. 
